INmune Bio (NASDAQ:INMB) is advancing its European commercialization strategy for Ebstrocel, leveraging chemistry, manufacturing, and controls (CMC) progress to streamline its regulatory timeline and accelerate potential entry into the UK market. By submitting its final pre-marketing authorization application (pre-MAA) package to the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), the biotechnology company confirmed a major pivot: it will bypass a rolling submission in favour of
INmune Bio (NASDAQ:INMB) is advancing its European commercialization strategy for Ebstrocel, leveraging chemistry, manufacturing, and controls (CMC) progress to streamline its regulatory timeline and accelerate potential entry into the UK market. By submitting its final pre-marketing authorization application (pre-MAA) package to the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), the biotechnology company confirmed a major pivot: it will bypass a rolling submission in favour of
INmune Bio (NASDAQ:INMB) is advancing its European commercialization strategy for Ebstrocel, leveraging chemistry, manufacturing, and controls (CMC) progress to streamline its regulatory timeline and accelerate potential entry into the UK market. By submitting its final pre-marketing authorization application (pre-MAA) package to the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), the biotechnology company confirmed a major pivot: it will bypass a rolling submission in favour of
